weekly_roundup
BioTechSign Daily Catalyst Roundup - November 01, 2026
Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 1, 2026
Daily Biotech Catalyst Digest: November 01, 2026
ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| ITCI | Intra-Cellular Therapies | 100.0 | A | clinical activity 100% |
| DCPH | Deciphera Pharmaceuticals | 100.0 | A | clinical activity 100% |
| BGNE | BeiGene Ltd | 100.0 | A | publication signal 100%, clinical activity 100% |
| AKBA | Akebia Therapeutics | 87.2 | A | clinical activity 92%, short interest 50% |
| RGNX | REGENXBIO Inc | 86.4 | A | publication signal 100%, clinical activity 100%, short interest 70% |
| SRPT | Sarepta Therapeutics | 85.9 | A | clinical activity 100%, short interest 70%, dilution risk 48% |
Recent Grade-Change Queue
- SLDB (Solid Biosciences) currently grades D with a 45.8/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, clinical activity 67%.
- PRQR (ProQR Therapeutics) currently grades D with a 49.4/100 catalyst score. Main inputs: publication signal 100%, clinical activity 54%, dilution risk 46%.
- LYEL (Lyell Immunopharma) currently grades D with a 41.7/100 catalyst score. Main inputs: publication signal 100%, dilution risk 61%, clinical activity 58%.
- MBRX (Moleculin Biotech) currently grades D with a 39.9/100 catalyst score. Main inputs: dilution risk 92%, publication signal 80%, clinical activity 50%.
- LRMR (Larimar Therapeutics) currently grades D with a 41.0/100 catalyst score. Main inputs: short interest 70%, dilution risk 41%, clinical activity 38%.
- KNSA (Kiniksa Pharmaceuticals) currently grades D with a 39.7/100 catalyst score. Main inputs: clinical activity 50%, short interest 30%, dilution risk 11%.
- IMV (IMV Inc) currently grades D with a 37.5/100 catalyst score. Main inputs: clinical activity 38%.
- GERN (Geron Corporation) currently grades B with a 67.8/100 catalyst score. Main inputs: publication signal 100%, clinical activity 75%, dilution risk 50%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.